Abstract: An electrical plug-in connector for differential signal transmission, having an external conductor contact element, a dielectric and at least one internal conductor contact element pair for differential signal transmission. The dielectric extends along a longitudinal axis through the external conductor contact element. The internal conductor contact element pair has a first internal conductor contact element and a second internal conductor contact element which extend along the longitudinal axis through the dielectric. The external conductor contact element and/or the dielectric have a compensation geometry in order to compensate for an asymmetry of the internal conductor contact element pair with respect to the longitudinal axis. As an alternative or in addition, it is provided that the internal conductor contact element pair has a compensation geometry in order to compensate for an asymmetry of the external conductor contact element and/or of the dielectric with respect to the longitudinal axis.

Abstract: A semiconductor device includes: a semiconductor region having charge carriers of a first conductivity type; a transistor cell in the semiconductor region; a semiconductor channel region in the transistor cell and having a first doping concentration of charge carriers of a second conductivity type, wherein a transition between the semiconductor channel region and the semiconductor region forms a first pn-junction; a semiconductor auxiliary region in the semiconductor region and having a second doping concentration of charge carriers of the second conductivity type. A transition between the semiconductor auxiliary region and semiconductor region forms a second pn-junction positioned deeper in the semiconductor region as compared to the first pn-junction.

Abstract: A seating unit for use in a space including a supporting floor surface, the seating unit comprising a seat structure comprising a mounting bracket having a female connector, a tablet assembly comprising a support arm having a mounting collar on an end and a base having a lower end to be supported by the floor surface and including a base mounting assembly and wherein the base mounting assembly comprises a cup attached to the base, a base tube having a first end inserted into the cup and a second end extending through the mounting collar and mateably engaging the female connector.

Abstract: A method for oxidizing an alkyl, including a) contacting the alkyl with an aqueous solution comprising a microorganism where the microorganism has a reduced fatty acid degradation capacity compared to its wild type, wherein the fatty acid degradation capacity is reduced by deletion, inhibition or inactivation of a gene encoding an enzyme involved in the ?-oxidation pathway; and the microorganism expresses a recombinant alkane oxidase, and b) contacting the aqueous solution from a) with a water-immiscible organic solvent.

Abstract: A semiconductor device is operable a forward current mode and a reverse current mode and comprises a semiconductor region, and a controllable charge carrier injector, and a gate. A method includes detecting, in the reverse current mode, if the present load current in the reversed direction does not exceed a threshold value, providing a gate signal such that the gate electrode causes the charge carrier injector to induce a first charge carrier density within the semiconductor region so as to conduct a nominal load current in the reverse direction; if the present load current in the reverse direction does exceed the threshold value, operating the semiconductor device in an overload state by providing the gate signal with a voltage that causes the semiconductor region to conduct an overload current in the reverse direction, wherein the second charge carrier density is higher than the first charge carrier density.

Abstract: The present invention relates to the use as fungicides of compounds of formula (I) wherein the variables are defined as given in the description and claims. The invention further relates to the compounds I and composition for compounds of formula I.

Abstract: A method of treating irritable bowel syndrome in a patient in need thereof by administering to said patient a pharmaceutically effective amount of tapentadol.

Abstract: An aqueous pharmaceutical composition adapted for parenteral administration of tapentadol or a physiologically acceptable salt thereof having a pH value of at least 5.4.

Abstract: The invention relates to a pharmaceutical composition comprising Tapentadol or a physiologically acceptable salt thereof for use in local anesthesia.

Abstract: The invention relates to a pharmaceutical patch comprising a Lidocaine constituent and a Diclofenac constituent, wherein the relative weight content ratio of the Lidocaine constituent to the Diclofenac constituent is within the range of from about 7:1 to about 4:1, based on the equivalent weight of the non-salt form of Lidocaine and of Diclofenac, for use in the local treatment or prevention of pain, wherein the pain is neuropathic pain or wherein the pain has a neuropathic pain component. The pharmaceutical composition is suitable for topical administration and local pharmacological action via delivery of Lidocaine and Diclofenac into the skin and possibly also through and to other deeper tissues such as the synovial fluid without significant systemic exposure.

Abstract: The invention relates to a pharmaceutical patch comprising a Lidocaine constituent and a Diclofenac constituent, wherein the relative weight content ratio of the Lidocaine constituent to the Diclofenac constituent is within the range of from about 7:1 to about 4:1, based on the equivalent weight of the non-salt form of Lidocaine and of Diclofenac, for use in the local treatment or prevention of pain. The pharmaceutical composition is suitable for topical administration and local pharmacological action via delivery of Lidocaine and Diclofenac into the skin and possibly also through and to other deeper tissues such as the synovial fluid without significant systemic exposure.

Abstract: The use of tapentadol for the treatment of pain associated with disorders of the trigeminal nerve, in particular for use in the treatment of pain associated with trigeminal neuralgia.

Abstract: The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient selected from (1r,4r)-6?-fluoro-N,N-dimethyl-4-phenyl-4?,9?-dihydro-3?H-spiro [cyclohexane-1,1?-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient which is an antidepressant.

Abstract: A composition of matter comprising in combination as component (a) at least one 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol compound, and as component (b) at least one antiepileptic, a pharmaceutical formulation and a dosage form comprising said composition of matter, and a method of treating pain, e.g. neuropathic pain, in which components (a) and (b) are administered simultaneously or sequentially to a mammal, whereby component (a) may be administered before or after component (b) and whereby components (a) or (b) are administered to the mammal either via the same or a different pathway of administration.

Abstract: A composition of matter comprising in combination as component (a) at least one 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol compound, and as component (b) at least one antiepileptic, a pharmaceutical formulation and a dosage form comprising said composition of matter, and a method of treating pain, e.g. neuropathic pain, in which components (a) and (b) are administered simultaneously or sequentially to a mammal, whereby component (a) may be administered before or after component (b) and whereby components (a) or (b) are administered to the mammal either via the same or a different pathway of administration.

Abstract: A method of treating irritable bowel syndrome in a patient in need thereof by administering to said patient a pharmaceutically effective amount of tapentadol.

Abstract: The invention relates to oxazole and thiazole-based carboxamide and urea derivatives as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

Abstract: The invention relates to oxazole and thiazole-based carboxamide and urea derivatives as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

Abstract: A method of treating irritable bowel syndrome in a patient in need thereof by administering to said patient a pharmaceutically effective amount of tapentadol.

Abstract: The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient selected from (1r,4r)-6?-fluoro-N,N-dimethyl-4-phenyl-4?,9?-dihydro-3?H-spiro[cyclohexane-1,1?-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient selected from gabapentinoids and the physiologically acceptable salts thereof.